For Immediate Release
Closes $28.75 Million Underwritten Public Offering
of its American
Tel Aviv, Israel - April 5, 2017 - BioLineRx Ltd. (NASDAQ/TASE:
BLRX), a clinical stage biopharmaceutical development company focused on oncology and immunology, today announced that it has closed
its previously announced underwritten public offering of approximately 33.8 million American Depositary Shares (“ADSs”),
each representing one (1) of its ordinary shares, at a public offering price of $0.85 per ADS, for gross proceeds of $28.75 million,
before deducting underwriting discounts and commissions and estimated offering expenses payable by BioLineRx. All of the ADSs in
the offering were sold by BioLineRx. The amount of ADSs sold includes an additional approximately 4.4 million ADSs purchased
by the underwriters pursuant to the option granted to them by BioLineRx. BioLineRx anticipates using the net proceeds from the
offering to fund a number of clinical trials, including for BL-8040 and AGI-134, and for working capital and general corporate
JMP Securities acted as sole book-running manager for the offering.
H.C. Wainwright & Co., LLC acted as lead manager. Maxim Group
acted as co-manager.
The ADSs were issued pursuant to a shelf registration statement
that was previously filed with, and declared effective by, the Securities and Exchange Commission (“SEC”). A final
prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's website located at www.sec.gov.
This press release does not constitute an offer to sell or a solicitation
of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation
or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any
offer, if at all, will be made only by means of a prospectus supplement and accompanying prospectus forming a part of the effective
registration statement, copies of which may be obtained, when available, from JMP Securities LLC, 600 Montgomery Street, Suite
100, San Francisco, California 94111, Attention: Prospectus Department, or by telephone: (415) 835-8985.
BioLineRx is a clinical-stage biopharmaceutical company focused
on oncology and immunology. The Company in-licenses novel compounds, develops them through pre-clinical and/or clinical stages,
and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.